The objective of a study was to evaluate the efficacy of Ivermectin and combined Ivermectin and Metronidazole therapy in the treatment of ocular and skin lesions of Demodex folliculorum.
One hundred twenty patients with skin lesions and anterior blepharitis, whose infestation was treatment-resistant and who had a Demodex count more than 5 mites/cm2 for skin lesions or greater than or equal to 3 mites at the root of each eyelash, were recruited.
The treatment regimens were Ivermectin and Ivermectin - Metronidazole combined therapy.
Researchers enrolled 15 patients from each of four groups for each treatment regimen.
Demodex was detected by standardized skin surface biopsy for skin lesions. Three eyelashes from each affected lower eyelid were epilated and examined.
The study subjects were followed-up once a week for four visits.
There was a difference in the mite count between the subgroups taking Ivermectin and combined therapy during all follow-up visits. At the last visit, in the combined therapy subgroup, 1.7% of patients showed no clinical improvement, 26.7% showed a marked clinical improvement, and 71.6% showed complete remission.
In those on the Ivermectin regimen, 27 patients had a mite count more than 5 mites/cm2, 21.7% showed no clinical improvement, 33.3% showed a marked improvement, and 45% showed complete remission.
In conclusion, combined therapy was superior in decreasing the Demodex folliculorum count in all groups and in reducing the mite count to the normal level in rosacea and in anterior blepharitis.
On the other hand, the two regimens were comparable in reducing the mite count to the normal level in acne and peri-oral dermatitis lesions. ( Xagena )
Salem DA et al, Int J Infect Dis 2013;17:e343